NeuroVive Asia Signs Collaboration Agreement With Sanofi For The Development And Commercialization Of Ciclomulsion In South Korea

NeuroVive Pharmaceutical AB (STO:NVP), the mitochondrial medicine company, announces that NeuroVive Pharmaceutical Asia group has signed a collaboration agreement with Sanofi’s local affiliate for the development and commercialization of CicloMulsion® in South Korea. Under the agreement NeuroVive Asia will get an upfront payment, a conditional milestone payment and royalty on potential future sales in South Korea. CicloMulsion® is being developed for the treatment of reperfusion injury in cardiovascular disease.

Help employers find you! Check out all the jobs and post your resume.